Q-omics provides the consensus-scored CICP12 profile across patient tissues and cancer cell-line models. CICP12 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, CICP12 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, CICP12 RNA expression shows 6,761 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, KICH, and STAD as cancer lineages where CICP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP12 survival associations across molecular data types. CICP12 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP12 RNA expression–survival associations across cancer types. High CICP12 expression shows unfavorable associations in READ, KIRC, MESO, KICH and CHOL, but favorable associations in SKCM. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for CICP12 RNA expression.
This table summarizes CICP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CICP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP12 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, BLCA and KIRC. The KICH box plot shows higher CICP12 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p = .002).
This table shows molecular features associated with CICP12 in patient tissues and cancer cell lines. In patient samples, CICP12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
